[
  {
    "ts": null,
    "headline": "BofA downgrades Moderna, says it's 'tough time' to be vaccine maker",
    "summary": "Moderna (MRNA) shares tumble after Bank of America analysts reinstated its Underperform rating for the stock. In a broader note about the pharmaceutical and biotech spaces, Bank of America's team it's a \"tough time\" to be a vaccine maker. On the other hand, the analysts name Eli Lilly (LLY) as a \"core long-term holding.\" Julie Hyman and Josh Lipton take a closer look at the note and stock reactions on Market Domination Overtime. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here. This post was written by Naomi Buchanan.",
    "url": "https://finnhub.io/api/news?id=be9cfbefabae47e5d57b284af76145e0b33aeb05fe501dc376d01356692250f6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733870220,
      "headline": "BofA downgrades Moderna, says it's 'tough time' to be vaccine maker",
      "id": 131909788,
      "image": "https://s.yimg.com/ny/api/res/1.2/fMqebeBSMnc6wn75E_x1Yg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzY-/https://s.yimg.com/os/creatr-uploaded-images/2024-12/5f3ce460-b744-11ef-a9df-6c40215133cb",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Moderna (MRNA) shares tumble after Bank of America analysts reinstated its Underperform rating for the stock. In a broader note about the pharmaceutical and biotech spaces, Bank of America's team it's a \"tough time\" to be a vaccine maker. On the other hand, the analysts name Eli Lilly (LLY) as a \"core long-term holding.\" Julie Hyman and Josh Lipton take a closer look at the note and stock reactions on Market Domination Overtime. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here. This post was written by Naomi Buchanan.",
      "url": "https://finnhub.io/api/news?id=be9cfbefabae47e5d57b284af76145e0b33aeb05fe501dc376d01356692250f6"
    }
  },
  {
    "ts": null,
    "headline": "Asian Stocks Set for Sluggish Start as CPI Looms: Markets Wrap",
    "summary": "(Bloomberg) -- Asian shares were poised for a tepid opening as traders await key US inflation data for clues on whether the Federal Reserve will cut or hold rates next week.Most Read from BloombergBrace for a Nationwide Shuffle of Corporate HeadquartersCloud Computing Tax Threatens Chicago’s Silicon Valley DreamA Chicago Skyscraper Cements the Legacy of a Visionary Postmodern ArchitectSan Francisco, Paris Named Best Cities for Urban TransportationDC Business Leaders Welcome Return-to-Office Poli",
    "url": "https://finnhub.io/api/news?id=9c5d5a16c33603fab403b56e5301f9496fa6aefc5209f021eb8541c1833ec57a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733869787,
      "headline": "Asian Stocks Set for Sluggish Start as CPI Looms: Markets Wrap",
      "id": 131909790,
      "image": "https://s.yimg.com/ny/api/res/1.2/bsQAWL0bRuNDCIa0eCvMHA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD03NDE-/https://media.zenfs.com/en/bloomberg_markets_842/dc76a22ba1501ec258bf3b1e5de0938c",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "(Bloomberg) -- Asian shares were poised for a tepid opening as traders await key US inflation data for clues on whether the Federal Reserve will cut or hold rates next week.Most Read from BloombergBrace for a Nationwide Shuffle of Corporate HeadquartersCloud Computing Tax Threatens Chicago’s Silicon Valley DreamA Chicago Skyscraper Cements the Legacy of a Visionary Postmodern ArchitectSan Francisco, Paris Named Best Cities for Urban TransportationDC Business Leaders Welcome Return-to-Office Poli",
      "url": "https://finnhub.io/api/news?id=9c5d5a16c33603fab403b56e5301f9496fa6aefc5209f021eb8541c1833ec57a"
    }
  },
  {
    "ts": null,
    "headline": "Lilly CEO says tax and regulation reform, drug affordability are focuses under Trump",
    "summary": "Eli Lilly CEO David Ricks on Tuesday said at the Economic Club of Washington that tax and regulation reform and drug affordability were some policy focuses for the company in a second Trump administration.  It was also reported that Pfizer CEO Albert Bourla attended.  The Lilly CEO did not share details of that conversation during an interview with Carlyle Group cofounder David Rubenstein.",
    "url": "https://finnhub.io/api/news?id=9fe7a28f177c5967023098fb6fa1770046d2fac81021fa3ea8c75e2a0843c18d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733863737,
      "headline": "Lilly CEO says tax and regulation reform, drug affordability are focuses under Trump",
      "id": 131909792,
      "image": "https://media.zenfs.com/en/reuters.com/8812d4fa5996d021a4978e5a1d25bdf2",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly CEO David Ricks on Tuesday said at the Economic Club of Washington that tax and regulation reform and drug affordability were some policy focuses for the company in a second Trump administration.  It was also reported that Pfizer CEO Albert Bourla attended.  The Lilly CEO did not share details of that conversation during an interview with Carlyle Group cofounder David Rubenstein.",
      "url": "https://finnhub.io/api/news?id=9fe7a28f177c5967023098fb6fa1770046d2fac81021fa3ea8c75e2a0843c18d"
    }
  },
  {
    "ts": null,
    "headline": "For ESGV, Ethics Is Not A Drag",
    "summary": "Challenging a common prejudice, ESGV proves that some ethical principles in stock picking are not a drag on performance. Read the full ETF analysis here.",
    "url": "https://finnhub.io/api/news?id=564292357778d3dbef4ea1ba47eeb16f94d3b2f05ce01a2442a3230450c68889",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733854671,
      "headline": "For ESGV, Ethics Is Not A Drag",
      "id": 131909578,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2152386308/image_2152386308.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Challenging a common prejudice, ESGV proves that some ethical principles in stock picking are not a drag on performance. Read the full ETF analysis here.",
      "url": "https://finnhub.io/api/news?id=564292357778d3dbef4ea1ba47eeb16f94d3b2f05ce01a2442a3230450c68889"
    }
  },
  {
    "ts": null,
    "headline": "What's Going On With Eli Lilly Stock On Tuesday?",
    "summary": "On Monday, Eli Lilly And Co (NYSE:LLY) announced results from the Phase 3 BRUIN CLL-321 trial evaluating pirtobrutinib in adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) previously treated with a covalent BTK inhibitor. The study’s primary endpoint of progression-free survival (PFS) was met at primary analysis, demonstrating pirtobrutinib was superior to the investigator’s choice of idelalisib plus rituximab (IdelaR) or bendamustine plus rituximab (BR). A",
    "url": "https://finnhub.io/api/news?id=3f742d20a7344aa518ed300229f29774842373b439bf718b9ade37effc99b754",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733849526,
      "headline": "What's Going On With Eli Lilly Stock On Tuesday?",
      "id": 131906330,
      "image": "https://media.zenfs.com/en/Benzinga/e70b3edd02bc701a1b911e6d5cfb22a5",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "On Monday, Eli Lilly And Co (NYSE:LLY) announced results from the Phase 3 BRUIN CLL-321 trial evaluating pirtobrutinib in adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) previously treated with a covalent BTK inhibitor. The study’s primary endpoint of progression-free survival (PFS) was met at primary analysis, demonstrating pirtobrutinib was superior to the investigator’s choice of idelalisib plus rituximab (IdelaR) or bendamustine plus rituximab (BR). A",
      "url": "https://finnhub.io/api/news?id=3f742d20a7344aa518ed300229f29774842373b439bf718b9ade37effc99b754"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly & Co. stock underperforms Tuesday when compared to competitors",
    "summary": "Eli Lilly & Co. stock underperforms Tuesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=36d7e6e5572b5d4e8a2959784d9d39921f65a51be7792b39524e7510519317f8",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733848380,
      "headline": "Eli Lilly & Co. stock underperforms Tuesday when compared to competitors",
      "id": 131932780,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly & Co. stock underperforms Tuesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=36d7e6e5572b5d4e8a2959784d9d39921f65a51be7792b39524e7510519317f8"
    }
  },
  {
    "ts": null,
    "headline": "Lilly Will Test Obesity Drugs on Addiction, CEO Says",
    "summary": "-- Eli Lilly & Co. will begin studies to see if its blockbuster weight-loss medicines can also be used to treat addictive behaviors like alcohol abuse, smoking and drug addiction, Chief Executive...",
    "url": "https://finnhub.io/api/news?id=1510ee9a7dca92b8df84484cce1af88ce7c7563a8203bd0cc7708988e9179c63",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733845604,
      "headline": "Lilly Will Test Obesity Drugs on Addiction, CEO Says",
      "id": 131907179,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "-- Eli Lilly & Co. will begin studies to see if its blockbuster weight-loss medicines can also be used to treat addictive behaviors like alcohol abuse, smoking and drug addiction, Chief Executive...",
      "url": "https://finnhub.io/api/news?id=1510ee9a7dca92b8df84484cce1af88ce7c7563a8203bd0cc7708988e9179c63"
    }
  },
  {
    "ts": null,
    "headline": "BofA reinstates pharma coverage",
    "summary": "Investing.com -- Bank of America reinstated coverage of 11 major U.S. pharmaceutical and biotech stocks in a note Tuesday, highlighting mixed sector fundamentals.",
    "url": "https://finnhub.io/api/news?id=5d7eece3a855f9ed7f9ef4b6a54fd8dbc8d3d89cb0e656744539801a35d2ad65",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733841630,
      "headline": "BofA reinstates pharma coverage",
      "id": 131902817,
      "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investing.com -- Bank of America reinstated coverage of 11 major U.S. pharmaceutical and biotech stocks in a note Tuesday, highlighting mixed sector fundamentals.",
      "url": "https://finnhub.io/api/news?id=5d7eece3a855f9ed7f9ef4b6a54fd8dbc8d3d89cb0e656744539801a35d2ad65"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Steady Pre-Bell Tuesday",
    "summary": "Health care stocks were steady premarket Tuesday, with The Health Care Select Sector SPDR Fund (XLV)",
    "url": "https://finnhub.io/api/news?id=34d6962715bca4cc9887e763b0ae45d2885750ad9ae61ddd0ca834b09cc47107",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733839655,
      "headline": "Sector Update: Health Care Stocks Steady Pre-Bell Tuesday",
      "id": 131906332,
      "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Health care stocks were steady premarket Tuesday, with The Health Care Select Sector SPDR Fund (XLV)",
      "url": "https://finnhub.io/api/news?id=34d6962715bca4cc9887e763b0ae45d2885750ad9ae61ddd0ca834b09cc47107"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know",
    "summary": "Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=2c0a89048387ca3c177e7cd48996f9aafe1361d9ef2bb26ff9f4cbab1de746a2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733839218,
      "headline": "Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know",
      "id": 131906333,
      "image": "https://media.zenfs.com/en/zacks.com/2f0d6efdd8740952a371c97ddea6e926",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=2c0a89048387ca3c177e7cd48996f9aafe1361d9ef2bb26ff9f4cbab1de746a2"
    }
  },
  {
    "ts": null,
    "headline": "Pioneer Balanced ESG Fund Q3 2024 Performance And Market Commentary",
    "summary": "Pioneer Balanced ESG Fundâs Class Y shares returned 4.09% in the third quarter, underperforming the Fundâs equity and fixed income benchmarks. Read more here.",
    "url": "https://finnhub.io/api/news?id=342ef00ffdf9360c3d2a739a17135c531918eea0645a9234bd618c6fc0d2e531",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733836140,
      "headline": "Pioneer Balanced ESG Fund Q3 2024 Performance And Market Commentary",
      "id": 131905014,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1401878862/image_1401878862.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Pioneer Balanced ESG Fundâs Class Y shares returned 4.09% in the third quarter, underperforming the Fundâs equity and fixed income benchmarks. Read more here.",
      "url": "https://finnhub.io/api/news?id=342ef00ffdf9360c3d2a739a17135c531918eea0645a9234bd618c6fc0d2e531"
    }
  },
  {
    "ts": null,
    "headline": "Lilly Announces New $15B Stock Buyback Plan, Ups Dividend by 15%",
    "summary": "LLY's board approves a new $15B stock buyback plan and announces a 15% increase in its quarterly dividend.",
    "url": "https://finnhub.io/api/news?id=9851d384d83cf11ef89e49991d6ffd6add9a8fe4b108bca93b7e33659fd9fd40",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733834160,
      "headline": "Lilly Announces New $15B Stock Buyback Plan, Ups Dividend by 15%",
      "id": 131905570,
      "image": "",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "LLY's board approves a new $15B stock buyback plan and announces a 15% increase in its quarterly dividend.",
      "url": "https://finnhub.io/api/news?id=9851d384d83cf11ef89e49991d6ffd6add9a8fe4b108bca93b7e33659fd9fd40"
    }
  },
  {
    "ts": null,
    "headline": "Moderna Stock Is Struggling. BofA Doesn’t See Things Getting Better.",
    "summary": "Moderna Stock Is Struggling. BofA Doesn’t See Things Getting Better.",
    "url": "https://finnhub.io/api/news?id=1cfb5e96e3f9b934fda2b7984a7a5ff90e0b8e7d4a824c00c7f3e5b4bc2f07b9",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733830920,
      "headline": "Moderna Stock Is Struggling. BofA Doesn’t See Things Getting Better.",
      "id": 131932781,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Moderna Stock Is Struggling. BofA Doesn’t See Things Getting Better.",
      "url": "https://finnhub.io/api/news?id=1cfb5e96e3f9b934fda2b7984a7a5ff90e0b8e7d4a824c00c7f3e5b4bc2f07b9"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: further share buybacks and dividend increase",
    "summary": "Eli Lilly announced last night the launch of a new $15 billion share buyback program and a 15% dividend increase, two pieces of news that were greeted rather favorably on Tuesday by the New York Stock...",
    "url": "https://finnhub.io/api/news?id=f7eb51690405e8aced7325ff082edeb983affd502c838e1ad30be54dfb5febc6",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733826250,
      "headline": "Eli Lilly: further share buybacks and dividend increase",
      "id": 131902521,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Eli Lilly announced last night the launch of a new $15 billion share buyback program and a 15% dividend increase, two pieces of news that were greeted rather favorably on Tuesday by the New York Stock...",
      "url": "https://finnhub.io/api/news?id=f7eb51690405e8aced7325ff082edeb983affd502c838e1ad30be54dfb5febc6"
    }
  },
  {
    "ts": null,
    "headline": "3 US Stocks Estimated To Be Trading At Discounts Of Over 16.7%",
    "summary": "As the U.S. stock market experiences fluctuations amid ongoing discussions about inflation and interest rate adjustments, investors are keeping a close watch on economic indicators that could influence future Federal Reserve decisions. With major indices like the S&P 500 and Nasdaq Composite recently reaching record highs, identifying stocks that may be trading at a discount becomes particularly appealing for those looking to capitalize on potential value opportunities in this volatile...",
    "url": "https://finnhub.io/api/news?id=c7fe507794b6afb79d9786e89703bccdb4aba425607a018197f8004de826757d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733824984,
      "headline": "3 US Stocks Estimated To Be Trading At Discounts Of Over 16.7%",
      "id": 131899921,
      "image": "https://media.zenfs.com/en/simply_wall_st__316/4470f143ba4f4c0e99553a639759c619",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "As the U.S. stock market experiences fluctuations amid ongoing discussions about inflation and interest rate adjustments, investors are keeping a close watch on economic indicators that could influence future Federal Reserve decisions. With major indices like the S&P 500 and Nasdaq Composite recently reaching record highs, identifying stocks that may be trading at a discount becomes particularly appealing for those looking to capitalize on potential value opportunities in this volatile...",
      "url": "https://finnhub.io/api/news?id=c7fe507794b6afb79d9786e89703bccdb4aba425607a018197f8004de826757d"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights Eli Lilly, AbbVie, Gilead Sciences, Air T and Fossil Group",
    "summary": "Eli Lilly, AbbVie, Gilead Sciences, Air T and Fossil Group are included in this Analyst Blog.",
    "url": "https://finnhub.io/api/news?id=ca26fff1d5cb793489ed35def3676a8c50d60227996c5c720beed96308b4eec3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733824800,
      "headline": "The Zacks Analyst Blog Highlights Eli Lilly, AbbVie, Gilead Sciences, Air T and Fossil Group",
      "id": 131903660,
      "image": "https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly, AbbVie, Gilead Sciences, Air T and Fossil Group are included in this Analyst Blog.",
      "url": "https://finnhub.io/api/news?id=ca26fff1d5cb793489ed35def3676a8c50d60227996c5c720beed96308b4eec3"
    }
  },
  {
    "ts": null,
    "headline": "Swiss Re Says Too Early to Tell if Obesity Drugs Will Reshape Insurance",
    "summary": "Weight-loss drugs could be a boon for insurers, but it is too soon to tell whether the industry will be transformed, the head of Swiss Re’s life and health reinsurance arm said.",
    "url": "https://finnhub.io/api/news?id=fad372c7591cd47c5e0c42e36e093b569961743f2ad918f15addab4f72db35cf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733824800,
      "headline": "Swiss Re Says Too Early to Tell if Obesity Drugs Will Reshape Insurance",
      "id": 131900194,
      "image": "",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Weight-loss drugs could be a boon for insurers, but it is too soon to tell whether the industry will be transformed, the head of Swiss Re’s life and health reinsurance arm said.",
      "url": "https://finnhub.io/api/news?id=fad372c7591cd47c5e0c42e36e093b569961743f2ad918f15addab4f72db35cf"
    }
  },
  {
    "ts": null,
    "headline": "Warning: This Skyrocketing Stock Has a Hidden Risk",
    "summary": "This year the company reported solid results from trials of a candidate meant to address one of today's hottest growth areas: weight loss.  The weight loss drug market may reach $130 billion by 2030, according to Goldman Sachs Research, an increase from its earlier estimate of $100 billion.  Viking Therapeutics (NASDAQ: VKTX) saw its shares rise 121% in one trading session after its initial clinical trial report back in February.",
    "url": "https://finnhub.io/api/news?id=b8d0c91c521356ee4fea43a2ea89adbc8029f0868e5322cda2d1a6d67b194355",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733821800,
      "headline": "Warning: This Skyrocketing Stock Has a Hidden Risk",
      "id": 131899018,
      "image": "https://g.foolcdn.com/editorial/images/800265/gettyimages-1213513544.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "This year the company reported solid results from trials of a candidate meant to address one of today's hottest growth areas: weight loss.  The weight loss drug market may reach $130 billion by 2030, according to Goldman Sachs Research, an increase from its earlier estimate of $100 billion.  Viking Therapeutics (NASDAQ: VKTX) saw its shares rise 121% in one trading session after its initial clinical trial report back in February.",
      "url": "https://finnhub.io/api/news?id=b8d0c91c521356ee4fea43a2ea89adbc8029f0868e5322cda2d1a6d67b194355"
    }
  },
  {
    "ts": null,
    "headline": "Phase 3 results for Lilly's Jaypirca in covalent BTK inhibitor pre-treated chronic lymphocytic leukemia or small lymphocytic lymphoma to be presented at the 2024 ASH Annual Meeting",
    "summary": "INDIANAPOLIS - Eli Lilly and Company today announced results from the Phase 3 BRUIN CLL-321 trial evaluating pirtobrutinib, a non-covalent Bruton's tyrosine kinase inhibitor in adult patients with...",
    "url": "https://finnhub.io/api/news?id=0fc4ae5f378f592409a29b20b5131cbcc541d9587e38fe55e62d6f18fc3dcea7",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733817817,
      "headline": "Phase 3 results for Lilly's Jaypirca in covalent BTK inhibitor pre-treated chronic lymphocytic leukemia or small lymphocytic lymphoma to be presented at the 2024 ASH Annual Meeting",
      "id": 131901122,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "INDIANAPOLIS - Eli Lilly and Company today announced results from the Phase 3 BRUIN CLL-321 trial evaluating pirtobrutinib, a non-covalent Bruton's tyrosine kinase inhibitor in adult patients with...",
      "url": "https://finnhub.io/api/news?id=0fc4ae5f378f592409a29b20b5131cbcc541d9587e38fe55e62d6f18fc3dcea7"
    }
  },
  {
    "ts": null,
    "headline": "Market Leadership Is Narrow. Your Portfolio Shouldn't Be",
    "summary": "2024 S&P 500 Index performance has been among some of the strongest in history, adding to similarly strong performance in recent years.",
    "url": "https://finnhub.io/api/news?id=bfd2bc7d49a8be9e8448b2e327b0cec4e3ca01f178482b9dbb6cfe300de4b04a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733798400,
      "headline": "Market Leadership Is Narrow. Your Portfolio Shouldn't Be",
      "id": 131898207,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1477909330/image_1477909330.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "2024 S&P 500 Index performance has been among some of the strongest in history, adding to similarly strong performance in recent years.",
      "url": "https://finnhub.io/api/news?id=bfd2bc7d49a8be9e8448b2e327b0cec4e3ca01f178482b9dbb6cfe300de4b04a"
    }
  }
]